Point-of-Care (POC) Infectious Disease Diagnostics Market Report 2021-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Point-of-Care (POC) Infectious Disease Diagnostics industry overview and then goes into each and every detail.
Point-of-Care (POC) Infectious Disease Diagnostics Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Point-of-Care (POC) Infectious Disease Diagnostics also provides data about the company and its operations. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the company.
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/63
Point-of-care (POC) diagnosis includes sample testing to facilitate rapid diagnosis and decide on treatment planning accordingly. Infectious diseases often need to be diagnosed early, as they can be fatal against the immune system. POC infectious disease diagnostics allows early detection of diseases and can impact the medical outcome of treatment of the disease.
The U.S. FDA (United States Food and Drug Administration) is responsible for overseeing all activities related to the marketing of diagnostic products. POC diagnosis is cost-efficient and time saving, as well as offer various benefits such as can be performed easily, prevent sample spillage, no necessity of skilled professionals, etc.
Market Dynamics:
The emergence of COVID-19 (SARS-CoV-2) is expected to propel the growth of the point-of-care (POC) infectious disease diagnostics market. For instance, in February 2021, RNA Disease Diagnostics secured an exclusive global license to a cutting-edge sensor technology jointly owned by the University of Maryland, Baltimore County (UMBC) and the University of Maryland, Baltimore (UMB). RNA Disease Diagnostics’ first product will be a rapid point-of-care (POC) COVID-19 test with accuracy, sensitivity, and specificity that is comparable to the gold standard RT-PCR lab diagnostic.
Moreover, initiatives and funding from government and individual organizations for point-of-care (POC) infectious disease diagnostics are expected to augment the growth of the point-of-care (POC) infectious disease diagnostics market. For instance, in February 2021, Visby Medical secured US$ 12.3 million from the United States Biomedical Advanced Research and Development Authority to develop a next generation device to detect influenza and COVID-19 in a single point-of-care rapid PCR test and, subsequently, as an over-the-counter test for consumer use.
Increasing prevalence of infectious diseases in both developed and developing countries and increasing incidence of target conditions is also expected to fuel the growth of the point-of-care (POC) infectious disease diagnostics market. However, stringent and time-consuming regulatory policies and pricing pressure due to reimbursement cuts and budget constraints are expected to restrain the market growth.
Major players in the market are adopting various strategies, such as merger, acquisition, and collaboration, to enhance their market presence. For instance, in January 2021, Thermo Fisher Scientific announced a definitive agreement to acquire molecular diagnostics company Mesa Biotech for approximately US$ 450 million.
In September 2019, Abbott Laboratories and Sanofi collaborated to integrate glucose sensing and insulin delivery technologies to further simplify diabetes management.
Top Key Players Include In Point-of-Care (POC) Infectious Disease Diagnostics Market: Danaher Corporation, Abbott Laboratories, Alcon Laboratories, Inc., Hoffman-La Roche Ltd., Becton, Dickinson, and Company, Trinity Biotech Plc, AccuBioTech Co., Ltd. and Cardinal Health, Inc.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/63
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
